130 related articles for article (PubMed ID: 22969115)
1. A genetic snapshot of small cell lung cancer.
Rosell R; Wannesson L
Cancer Discov; 2012 Sep; 2(9):769-71. PubMed ID: 22969115
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
[TBL] [Abstract][Full Text] [Related]
3. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
4. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
[TBL] [Abstract][Full Text] [Related]
5. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
Guo MZ; Marrone KA; Spira A; Scott SC
Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
10. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
[TBL] [Abstract][Full Text] [Related]
11. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?].
Pujol JL; Roch B; Pujol CN; Goze C
Bull Cancer; 2018 Oct; 105(10):955-966. PubMed ID: 30100047
[TBL] [Abstract][Full Text] [Related]
13. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
14. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
Kim C; Wang XD; Liu Z; Hao J; Wang S; Li P; Zi Z; Ding Q; Jang S; Kim J; Luo Y; Huffman KE; Pal Choudhuri S; Del Rio S; Cai L; Liang H; Drapkin BJ; Minna JD; Yu Y
Sci Adv; 2024 Jan; 10(3):eadh2579. PubMed ID: 38241363
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer.
Zheng Y; Wang Z; Wei S; Liu Z; Chen G
Cancer Lett; 2021 Feb; 499():148-163. PubMed ID: 33253790
[TBL] [Abstract][Full Text] [Related]
16. Integrated Bioinformatics Analysis for Identificating the Therapeutic Targets of Aspirin in Small Cell Lung Cancer.
Gong L; Zhang D; Dong Y; Lei Y; Qian Y; Tan X; Han S; Wang J
J Biomed Inform; 2018 Dec; 88():20-28. PubMed ID: 30414472
[TBL] [Abstract][Full Text] [Related]
17. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
18. Target engagement imaging of PARP inhibitors in small-cell lung cancer.
Carney B; Kossatz S; Lok BH; Schneeberger V; Gangangari KK; Pillarsetty NVK; Weber WA; Rudin CM; Poirier JT; Reiner T
Nat Commun; 2018 Jan; 9(1):176. PubMed ID: 29330466
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA damage in SCLC.
Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
[TBL] [Abstract][Full Text] [Related]
20. Small-cell lung cancer: an update on targeted therapies.
Joshi M; Ayoola A; Belani CP
Adv Exp Med Biol; 2013; 779():385-404. PubMed ID: 23288650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]